Search the Newsreel

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported a beneficial ownership of 9.96% in CytomX Therapeutics (CTMX). This group collectively holds shared voting and dispositive power over 21,703,093 shares of common stock. The disclosure was made …

CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for CytomX Therapeutics (NASDAQ:CTMX) from $12.00 to $11.00, while maintaining an "overweight" rating. This new target suggests a potential upside of 227.19% from the stock's previous close. The adjustment follows CytomX Therapeutics' recent quarterly report, …

Magnachip Semiconductor (MX) Stock Rebounds As Margin Beat Eases Loss Concerns

Magnachip Semiconductor (NYSE: MX) posts Q2 2026 loss as FX and hedges bite

MAGNACHIP SEMICONDUCTOR Corp Q2 2026: Revenue $44.7M, EPS $(0.13) — 10-Q Summary

MAGNACHIP SEMICONDUCTOR Corp reported Q2 2026 results with revenue of $44.7M, a decrease from $47.62M in Q2 2025, and a net loss of $(4.82)M, resulting in a diluted EPS of $(0.13) compared to net income in the prior year. The decline was attributed to …

Methanex Stock Faces Fresh Pressure as Methanol Volatility Clouds the Earnings Outlook

Should You Buy TMX Group Limited (TSE:X) For Its Upcoming Dividend?

CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in CytomX Therapeutics by 49.7% in the first quarter, now owning 1.93 million shares worth $9.07 million. Despite missing analyst expectations for Q1 earnings and revenue, the company maintains a "Buy" rating from analysts with a …

CytomX Therapeutics (CTMX) Stock Faces Revenue Collapse As Pipeline Hopes Carry The Story

CytomX Therapeutics (CTMX) saw its stock edge up slightly despite a significant revenue collapse and widened net loss in Q2 2026. The company's future prospects heavily rely on the success of its drug pipeline, particularly the PROBODY platform and Varseta M, as legacy collaborations …

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages

Analysts have issued a "Buy" consensus rating for CytomX Therapeutics (NASDAQ:CTMX), with an average 12-month price target of $12.10, significantly higher than its current share price of $3.46. Despite this positive outlook, the company reported a wider-than-expected quarterly loss of $0.09 per share and …

CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight

CytomX Therapeutics is advancing its lead asset, Varetta M, towards a registrational study in late-line colorectal cancer, with promising preliminary progression-free survival data. Despite a significant revenue decline and increased operating expenses, the company maintains a solid financial runway, bolstered by an expanded collaboration …

CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside

CytomX Therapeutics, Inc. (CTMX) has seen its average 12-month price target cut slightly from $12.50 to $12.38 by 8 analysts. This updated target suggests a significant potential upside of approximately 267% from its August 6th closing price. The consensus rating among these analysts remains …

SMX (Security Matters) PLC (SMX) Stock News Today

This article provides current stock information for SMX (Security Matters) PLC (SMX), including its market cap and P/E TTM. It notes the stock price, its change, and advises that more news, earnings, and analyst ratings will be available soon. The page serves as a …

SMX (Security Matters) PLC (SMX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for SMX (Security Matters) PLC (SMX), detailing its current stock performance and key financial metrics like market cap and P/E ratio. It highlights the company's position within the Financial Technology (Fintech) & Infrastructure sector, presenting a peer comparison …

Magnachip (MX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Investor Relations - Mike BishopChairman - Camillo MartinoChief Executive Officer - Chae LeeChief Financial Officer - Shin Young Park TAKEAWAYS Total Consolidated Revenue -- $44.7 million, representing a …

State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics

State Street Corporation has reported a beneficial ownership of 5.4% in CytomX Therapeutics, Inc., holding 11,747,236 shares of common stock. The filing indicates shared voting power over 11,471,693 shares and shared dispositive power over all 11,747,236 shares, with no sole voting or dispositive power. …

TMX Group Consolidated Trading Statistics - July 2026

Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, including Alpha-X & Alpha DRK, and Montréal Exchange Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - TMX Group Limited today announced July 2026 trading statistics for its marketplaces - Toronto Stock Exchange, TSX Venture Exchange, …

CytomX Therapeutics Inc earnings missed, revenue fell short of estimates

CytomX Therapeutics Inc (NASDAQ: CTMX) reported second-quarter earnings per share of $-0.090, missing analyst estimates of $-0.080, and revenue of $1.41M, significantly below the consensus estimate of $11.33M. The company's stock is down 15.200% in the last three months but up 60.710% in the …

MagnaChip Semiconductor Corp (MX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for MagnaChip Semiconductor Corp (MX), noting that no earnings forecast score is currently available, but the industry average is 7.71. Analysts have set a price target of $4.00 for MX. The report also includes FAQs about expected revenue, …

CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises

CytomX (NASDAQ: CTMX) reported a significant decline in Q2 2026 revenue to $1.4 million, down from $18.7 million year-over-year, and a widened net loss of $20.7 million primarily due to decreased collaboration revenue and increased R&D spending. Despite the financial setbacks, the company maintained …

Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends

CytomX Therapeutics reported a wider-than-expected Q2 2026 loss and a significant revenue drop, but its stock remained stable due to a strong cash reserve, a new Regeneron milestone payment, and promising early data for its lead cancer drug, Varseta-M. The company is strategically shifting …

CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash

CytomX Therapeutics reported Q2 2026 results with $1.4 million in revenue and $25.2 million in operating expenses, resulting in a $23.8 million operating loss. The company holds $330.3 million in cash, equivalents, and investments, projecting a financial runway until at least the second half …

CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

CytomX Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The report is available through Refinitiv, and the full article can be accessed by TradingView users. This news was originally reported by Reuters.

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics reported Q2 2026 revenue of $1.4 million and a net loss of $20.7 million, ending the quarter with $330.3 million in cash, projecting a runway to at least 2H 2028. The company completed enrollment for its Varseta-M Phase 1 CRC monotherapy trial …

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) reported a Q2 loss of $0.09 per share, exceeding the Zacks Consensus Estimate of a $0.11 loss, marking an 18.18% surprise. However, the company missed revenue estimates significantly, posting $1.42 million against an expected $7.18 million. Shares have declined 21.4% year-to-date, …

CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report

CytomX Therapeutics, Inc. announced that its Chief Legal Officer, Alejandra Carvajal, has become a "reporting insider" by filing a Form 3. This initial insider report indicates no transactions in CytomX securities, and it includes a Power of Attorney for future Section 16-related actions. The …

CytomX Therapeutics Chief Legal Officer Alejandra Carvajal files initial beneficial ownership statement

CytomX Therapeutics' Chief Legal Officer, Alejandra Carvajal, has filed an initial beneficial ownership statement (Form 3). This news brief was generated by Public Technologies (PUBT) using AI, based on original content filed with the U.S. Securities and Exchange Commission (SEC) via EDGAR on August …

CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO

CytomX Therapeutics, Inc. (CTMX) granted its Chief Legal Officer, Alejandra Carvajal, 450,000 stock options and 100,000 Restricted Stock Units (RSUs) on August 3, 2026. The stock options have an exercise price of $3.17 per share and vest over four years, while the RSUs vest …

Wall Street Analysts Think Methanex (MEOH) Could Surge 30.92%: Read This Before Placing a Bet

Methanex (MEOH) closed the last trading session at $53.53, gaining 16.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …

There May Be Reason For Hope In Methanex's (TSE:MX) Disappointing Earnings

Magnachip (NYSE: MX) director awarded 48,810 new common shares

Magnachip Semiconductor Corp. director Chung Kyo-Hwa Liz was granted 48,810 shares of common stock on August 1, 2026, at a price of $0.0000 per share. This non-derivative award increased her direct holdings to 149,599 Magnachip common shares. The transaction was reported in a Form …

Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CytomX Therapeutics has appointed Alejandra Carvajal as its new Chief Legal Officer. Carvajal brings over 20 years of legal experience in the biopharmaceutical industry, with a strong background in corporate law, M&A, intellectual property, and compliance. This appointment is expected to bolster CytomX's leadership …